|1.||Sirtori, Cesare R: 7 articles (04/2008 - 05/2002)|
|2.||Chiesa, Giulia: 5 articles (03/2008 - 05/2002)|
|3.||Bisgaier, Charles L: 3 articles (04/2008 - 05/2002)|
|4.||Marchesi, Marta: 3 articles (04/2008 - 05/2002)|
|5.||Franceschini, Guido: 3 articles (11/2007 - 05/2002)|
|6.||Ibanez, Borja: 2 articles (08/2010 - 03/2008)|
|7.||Badimon, Juan J: 2 articles (08/2010 - 03/2008)|
|8.||Speidl, Walter S: 2 articles (08/2010 - 03/2008)|
|9.||Fuster, Valentin: 2 articles (08/2010 - 03/2008)|
|10.||Cimmino, Giovanni: 2 articles (08/2010 - 03/2008)|
03/18/2008 - "Rapid change in plaque size, composition, and molecular footprint after recombinant apolipoprotein A-I Milano (ETC-216) administration: magnetic resonance imaging study in an experimental model of atherosclerosis."
05/01/2005 - "Apolipoprotein A-I-Milano(AIM), a natural variant, not only inhibits the initiation and progression of atherosclerosis, but also makes the preexisting atherosclerotic lesions regress. "
04/01/2003 - "Furthermore, recombinant apolipoprotein A-I(Milano) has displayed remarkable atheroprotective activities and the possibility of directly reducing the burden of atherosclerosis in experimental models. "
03/03/1998 - "In comparison with 20-week-old untreated control mice, 25-week-old apo A-I(Milano)/PC-treated mice demonstrated no increase in aortic atherosclerosis (11 +/- 1% versus 10 +/- 4%, P=NS), a 40% reduction in lipid content (22 +/- 8% versus 13 +/- 8%, P=.01), and a 46% reduction in macrophage content (10.8 +/- 2% versus 5.8 +/- 2.9%; P=.03). "
03/03/1998 - "In this study, we tested the hypothesis that apo A-I(Milano)/PC would inhibit aortic atherosclerosis in apo E-deficient mice. "
|2.||Vascular Diseases (Vascular Disease)
04/01/2003 - "This review is aimed at providing an update on the experimental studies in which apolipoprotein A-I(Milano), produced as a recombinant protein, has displayed important effects in the treatment of vascular diseases. "
05/17/2002 - "Apolipoprotein A-I(Milano) (AIM), a natural variant of human apolipoprotein A-I, confers to carriers a significant protection against vascular disease. "
11/06/2007 - "Carriers of the apolipoprotein A-I(Milano) (apoA-I(M)) mutant have very low plasma high-density lipoprotein cholesterol (HDL-C) levels but do not show any history of premature cardiovascular disease or any evidence of preclinical vascular disease. "
12/01/2005 - "No evidence of premature vascular disease is found in apolipoprotein A-I(Milano) (apoA-I(M)) human carriers, despite very low high density lipoprotein (HDL) cholesterol levels. "
|3.||Coronary Disease (Coronary Heart Disease)
04/01/2003 - "The mutant apolipoprotein A-I(Milano) has been associated with a reduced incidence of coronary disease in carriers. "
02/23/2007 - "Carriers of the apolipoprotein A-I(Milano) (A-I(M)) variant present with severe reductions of plasma HDL levels, not associated with premature coronary heart disease (CHD). "
04/17/2001 - "Carriers of the apolipoprotein A-I(Milano) (apoA-I(M)) mutant present with very low plasma HDL cholesterol and moderate hypertriglyceridemia, apparently not leading to premature coronary heart disease. "
|4.||Atherosclerotic Plaque (Atheroma)
08/01/2010 - "Recombinant apolipoprotein A-I Milano (rApoA-I(M)) induces atherosclerotic plaque regression. "
03/01/2007 - "Synthetically produced recombined apolipoprotein A-I Milano administered intravenously seems to have a marked effect in reducing the atheroma burden. "
03/07/2006 - "Relationship between atheroma regression and change in lumen size after infusion of apolipoprotein A-I Milano."
01/01/2003 - "Recombinant apolipoprotein A-I(Milano): a novel agent for the induction of regression of atherosclerotic plaques."
04/01/2003 - "In the past year, two reports have appeared, indicating that a single-dose administration of recombinant apolipoprotein A-I(Milano) dimers formulated into liposomes can reduce atheromas in models such as the apolipoprotein E-deficient mice and a rabbit model of carotid focal lesion, in which a direct 90 min infusion of the product reduced atheroma up to 30%. "
|5.||Acute Coronary Syndrome
|1.||Apolipoprotein A-I (Apolipoprotein A1)
|5.||Apolipoproteins E (ApoE)
|2.||Homologous Transplantation (Allograft)